Niagen Bioscience, Inc. Common Stock NAGE Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 64.3%+1.8pp | 64.3%+2.4pp | 63.9%+2.4pp | 63.6%— | 62.5%— | |
| Operating margin | 10%-2.2pp | 12.6%+4.8pp | 15.5%+15.0pp | 14.3%— | 12.3%— | |
| Net margin | 14.3%+1.2pp | 13.4%+4.8pp | 16.4%+14.9pp | 15.2%— | 13.1%— | |
| EBITDA margin | 10.7%-2.3pp | 13.2%+4.6pp | 16.1%+14.7pp | 15%— | 13%— | |
| Returns | ||||||
| Return on equity | 27.1%-6.4pp | 28.3%+5.4pp | 38.9%+34.4pp | 37.4%— | 33.5%— | |
| Return on assets | 19%— | 19.9%— | 26.4%— | —— | —— | |
| Return on invested capital | 114.6%— | 167.3%— | 259.4%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 1.3×— | 1.5×— | 1.6×— | —— | —— | |
| Inventory turnover | 2.6×— | 3.1×— | 3.1×— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 4.6×+0.9× | 4.9×+1.3× | 4.1×+1.2× | 3.9×— | 3.7×— | |
| Quick ratio | 3.6×+0.4× | 3.8×+0.8× | 3.3×+0.9× | 3.2×— | 3.1×— | |
| Cash ratio | 2.9×+0.2× | 3.3×+0.8× | 2.8×+1.0× | 2.7×— | 2.7×— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0.1×— | 0.1×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | 0×— | |
| Net debt / EBITDA | -4.6×— | -3.6×— | -3×— | -3.3×— | —— | |
| Interest coverage | 7.2×-2.7× | 8.5×+1.7× | 9.9×+9.5× | 10×— | 9.8×— | |
| Per Share | ||||||
| Book value per share | $0.97+46.4% | $0.90+51.8% | $0.82+84.6% | $0.74+83.1% | $0.66+72.8% | |
| Valuation | ||||||
| Market capitalization | $254.07M-74.9% | —— | —— | —— | —— | |
| Enterprise value | $190.09M-79.7% | —— | —— | —— | —— | |
| Price / earnings | 13.6×-43.5× | —— | —— | —— | —— | |
| Price / sales | 2×-6.8× | —— | —— | —— | —— | |
| Price / book | 3.3×-13.6× | —— | —— | —— | —— | |
| EV / EBITDA | 15×-44.1× | —— | —— | —— | —— | |
| EV / sales | 1.6×-7.3× | —— | —— | —— | —— | |
| Earnings yield | 6.8%+5.2pp | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Niagen Bioscience, Inc. Common Stock's profit margins?
- Niagen Bioscience, Inc. Common Stock (NAGE) runs a 64.3% gross margin and a 10.0% operating margin, with a 14.3% net margin.
- Where do Niagen Bioscience, Inc. Common Stock's ratios come from?
- Every ratio is computed from Niagen Bioscience, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
